Together, these results revealed a new role of GLUT1 glycosylation, suggesting that increasing GLUT1 glycosylation and membrane trafficking can promote bladder cancer progression which might provide a scientific basis for new drug development. This evidence concerns the gene SLC2A1 and urinary bladder cancer.